Governance
KHI’s governance framework ensures transparency, accountability, and collaborative decision-making across all initiatives. Our leadership includes voices from industry, patient advocacy, research, and government—working together to guide our mission.
- The KHI Board of Directors is charged with executing the consortium’s mission and objectives. It includes the Strategy, Biologics, Devices, and Drugs Committees.
- KHI’s governance and oversight structure was updated in 2022, revising the charge and governance of its committees and frameworks for defining strategy and approving activities. For more details, read the KHI Board of Directors Governance Task Force Executive Summary.
- The KHI PFPC advises and makes recommendations on projects and other activities to ensure that the voice, experiences, and involvement of people with kidney diseases are included in the development of kidney drugs, devices, and biologics.